Pharmaceutical

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.

Aug 28, 2023 - 20:00
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Read the original article

Tags:

Previous Article

Lutetium (lu177) lilotomab satetraxetan by Thor Medical for B-Cell Chronic Lymph...

Next Article

BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Physicians highlight need for improved non-opioid treatments for opioid use disorder

Physicians highlight need for improved non-opioid treat...

Sep 28, 2024

STAT+: Biden changes will force health insurers to speed up and get more specific if they want to deny care

STAT+: Biden changes will force health insurers to spee...

Jan 18, 2024

Soft, stretchable electronic skin could reconstruct the sense of touch

Soft, stretchable electronic skin could reconstruct the...

May 19, 2023